221 related articles for article (PubMed ID: 18184966)
1. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.
Paul E; Thiele E
N Engl J Med; 2008 Jan; 358(2):190-2. PubMed ID: 18184966
[No Abstract] [Full Text] [Related]
2. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
Davies DM; Johnson SR; Tattersfield AE; Kingswood JC; Cox JA; McCartney DL; Doyle T; Elmslie F; Saggar A; de Vries PJ; Sampson JR
N Engl J Med; 2008 Jan; 358(2):200-3. PubMed ID: 18184971
[No Abstract] [Full Text] [Related]
3. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
Franz DN; Krueger DA
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):365-373. PubMed ID: 30307123
[TBL] [Abstract][Full Text] [Related]
5. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
[TBL] [Abstract][Full Text] [Related]
8. [Recent advance in tuberous sclerosis-related genes and their expression].
Liu J; Piao YS; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):210-2. PubMed ID: 20450774
[No Abstract] [Full Text] [Related]
9. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
10. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex: tumors and tumorigenesis.
Borkowska J; Schwartz RA; Kotulska K; Jozwiak S
Int J Dermatol; 2011 Jan; 50(1):13-20. PubMed ID: 21182496
[TBL] [Abstract][Full Text] [Related]
12. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
13. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
[TBL] [Abstract][Full Text] [Related]
14. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex and lymphangioleiomyomatosis: miles to go, promises to keep.
Henske E
Ann Intern Med; 2011 Jun; 154(12):840-1. PubMed ID: 21690600
[No Abstract] [Full Text] [Related]
17. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?
Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M
Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185
[TBL] [Abstract][Full Text] [Related]
18. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
19. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
20. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
